Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato
California
94949
United States
Tel: 415-483-8800
Fax: 415-483-8810
Website: http://www.ultragenyx.com/careers/
Email: info@ultragenyx.com
About Ultragenyx Pharmaceutical Inc.
Founded in 2010, Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.
Where others turn away or take the road well traveled, we run towards the unknown and blaze new trails. We’re working hard to create treatments where none exist, giving new hope to patients with rare genetic diseases. Because you can only make a meaningful impact when your team has big ambitions. Join Ultragenyx and put your passion to work.
ultrafocused
Ultragenyx is dedicated to fostering a workplace environment that keeps our team inspired and provides the vision, resources and support they need to succeed. That includes maintaining a healthy, inclusive company culture where employees feel respected and valued. And providing opportunities for learning, personal growth, and career advancement. At Ultragenyx we push each other to perform at our very best, because we never lose sight of our mission – to make a difference in our patients’ lives.
268 articles with Ultragenyx Pharmaceutical Inc.
-
Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New Gene Therapies for Duchenne Muscular Dystrophy
10/23/2020
Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare diseases, and Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne),
-
Ultragenyx to Host Conference Call for Third Quarter 2020 Financial Results and Corporate Update
10/21/2020
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Tuesday, October 27, 2020 at 5pm ET to discuss third quarter 2020 financial results and provide a corporate update.
-
BioSpace Movers & Shakers, Sept. 4
9/4/2020
Biopharma and life science companies from across the globe strengthen their leadership teams and boards with these Movers & Shakers. -
Ultragenyx to Present at Upcoming Investor Conferences - Sep 03, 2020
9/3/2020
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the following upcoming investor conferences
-
Ultragenyx Appoints Mardi C. Dier as Chief Financial OfficerMs. Dier will start in new role in November 2020
9/2/2020
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it has appointed Mardi C. Dier as Executive Vice President and Chief Financial Officer (CFO), effective November 2, 2020.
-
Ultragenyx Expands Leadership Team and Appoints Ernie Meyer as Chief Human Resources Officer
9/1/2020
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it has appointed Ernie Meyer as Executive Vice President and Chief Human Resources Officer, effective September 1, 2020.
-
Ultragenyx to Present at Upcoming Investor Conferences - Aug 04, 2020
8/4/2020
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, announced that it will hold virtual presentations at the following upcoming investor conferences:
-
Ultragenyx Reports Second Quarter 2020 Financial Results and Corporate Update
7/30/2020
Two U.S. FDA approvals in second quarter 2020 Second quarter 2020 total revenue of $61.7 million and Crysvita revenue in Ultragenyx territories of $32.4 million Maintains full year 2020 guidance based on global COVID-19 impact to date
-
Ultragenyx to Host Conference Call for Second Quarter 2020 Financial Results and Corporate Update
7/24/2020
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Thursday, July 30, 2020 at 5pm ET to discuss second quarter 2020 financial results and provide a corporate update. The live and replayed webcast of the call will be available through the company’s we
-
Ultragenyx Announces U.S. Commercial Launch of Dojolvi™ (triheptanoin), the First FDA-Approved Therapy for the Treatment of Long-chain Fatty Acid Oxidation DisordersEstablished UltraCare® Program Provides Ongoing Patient Support Services
7/22/2020
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare diseases, today announced that Dojolvi™ (triheptanoin) is now commercially available. The U.S. Food and Drug Administration (FDA) approved Dojolvi on June 30, 2020 as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed l
-
Wrapping up the month of July, there are three PDUFA dates on the U.S. Food and Drug Administration (FDA) calendar.
-
PANTHERx® Rare Pharmacy Selected by Ultragenyx Pharmaceutical to Distribute DOJOLVI™ (triheptanoin), for Patients with Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)
7/2/2020
PANTHERx® Rare Pharmacy announces that it has been selected by Ultragenyx Pharmaceutical as a limited distribution partner for new drug DOJOLVI™ (triheptanoin).
-
Ultragenyx Announces U.S. FDA Approval of Dojolvi™ (UX007/triheptanoin), the First FDA-Approved Therapy for the Treatment of Long-chain Fatty Acid Oxidation Disorders
6/30/2020
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Dojolvi™
-
Crysvita is a drug developed by Ultragenyx Pharmaceutical and Tokyo-based Kyowa Kirin Co. Ltd., a specialty pharmaceutical company.
-
Ultragenyx and Kyowa Kirin Announce U.S. FDA Approval of Crysvita® (burosumab) for the Treatment of Tumor-Induced Osteomalacia (TIO)
6/18/2020
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare diseases, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions using the latest biotechnology, today announced that the U.S. Food and Drug Administration (FDA) has approved Crysvita®
-
Ultragenyx to Present at Upcoming Investor Conferences in June 2020
5/28/2020
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, announced that it will hold virtual presentations at the following upcoming investor conferences
-
Ultragenyx Announces Exercise of Option to Purchase Additional Stock of Arcturus Therapeutics
5/21/2020
Ultragenyx Pharmaceutical, Inc. (Nasdaq: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases and Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT), a leading messenger RNA medicines company, today announced that Ultragenyx has exercised its option to purchase 600,000 shares of Arcturus common stock at $16.00 per share. “We are enco
-
Ultragenyx Announces Positive Data from Confirmatory Cohort of Phase 1/2 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
5/15/2020
All Patients in Cohort 3 Demonstrate Increased Time to Hypoglycemia and a Substantial Reduction in Cornstarch Use Introduction of Continuous Glucose Monitoring Reveals Early Transgene Expression and Enables More Rapid Reduction in Cornstarch Ultragenyx to Host ASGCT Recap Investor Conference Call today at 8:30 a.m. Eastern Time NOVATO, Calif., May 15, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and comme
-
Ultragenyx Announces Positive Longer-term Results from First Three Cohorts of Phase 1/2 Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency
5/13/2020
Ultragenyx Pharmaceutical Inc. announced positive longer-term safety and efficacy data from the first three cohorts of the ongoing Phase 1/2 study of DTX301, an investigational adeno-associated virus gene therapy for the treatment of ornithine transcarbamylase deficiency.
-
Ultragenyx to Present at BofA Securities Global Health Care Conference
5/11/2020
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, announced that Shalini Sharp, the company's Chief Financial Officer, will hold a virtual presentation at the BofA Securities Global Health Care Conference on Thursday, May 14, 2020 at 10:20 AM ET.